![]() Of the 1001 case-patients, sixteen reported persistent breathlessness and none had dyspnoea more than grade 3 of mMRC dyspnoea scale. Weight loss (40%), Hair loss (29%), Fatigue/Tiredness (26%), myalgia (10%), and sleeplessness (9%) were the most common reported symptoms ( Figure 1). Four percent of those who remained asymptomatic during the active phase of infection also reported symptoms. Persistent symptoms were higher among the age group 45-59 years (40%), followed by 30-44 years (24%). Among the 249 who reported symptoms post recovery, 136 (55%) were males. Almost one in four (24%) reported at least one of the symptoms as persistent ( Figure 1 Among the hospitalised, 137 (28%) required oxygen support. All the 482 who were hospitalised either had a comorbidity or required oxygen therapy. Eight-hundred and fifty-two (85%) of the case-patients experienced symptoms during active phase of COVID-19, 482 (48%) were hospitalised. The mean age (SD) of the case-patients was 46.9 (16.1) years and 596 (60%) were females, 341 (34%) had at least one of the comorbidities. We contacted all the 1241 case-patients who were found positive for COVID-19 between February 25, 2021, and March 09, 2021. P value <0.05 was considered as statistically significant. We computed the adjusted OR (aOR) with 95% CI using multiple logistic regression after adjusting for age, gender, having any comorbidity, and hospitalisation. We estimated odds ratio (OR) with 95% confidence interval (95% CI) for the association between hospitalization, persistent symptoms and functional limitations. 7 Mean, Standard deviation (SD), and proportions were calculated as appropriate. ![]() The team graded the persistent breathlessness reported by the participants using modified Medical Research Council (mMRC) dyspnoea scale. 6 The PCFS was evaluated between the time of the interview and the pre-COVID-19 diagnosis. They also evaluated the functional status of activities of daily living using post COVID-19 functional scale (PCFS). The team collected data on persistent symptoms and ruled out the possible differential diagnosis based on the reported symptoms. ![]() A team of doctors tele-consulted all these COVID-19 case-patients aged >18 years during the 12-14 post recovery period of COVID-19. 1 The assessment was done during June 11-20, 2021. We defined persistent Post COVID-19 symptoms as clinical symptoms that develop during or after an infection consistent with COVID-19, persistent for more than 12 weeks and are not attributable to alternative clinical diagnoses. ![]() During the period, RT-PCR was the only method of testing and having any of the comorbidity or requiring oxygen therapy were the criteria for hospitalization. We obtained the line list of COVID-19 positive cases between February 25 and March 09, 2021, from the COVID-19 surveillance unit of Chennai, India. We rapidly assessed the burden of persistent post COVID-19 symptoms and functional status after 12-14 weeks among those recovered from COVID-19 in Chennai, Tamil Nadu, India. Understanding the burden of post COVID-19 symptoms is vital in planning the health systems for essential Post COVID care. 5 The proportion of the Indian Population who have been experiencing the symptoms following the recovery is unknown. 2, 3, 4 Long COVID symptoms were reported in 12 countries and none were from LMIC. Multiple articles published in the Journal of Infection discussed the persistent symptoms, quality of life, and functional status post recovery. 1 The knowledge about long COVID-19 is evolving day by day. Clinicians worldwide called these long-term effects of COVID-19 as “Long-Haul COVID-19”. However, a substantial proportion of patients who have been infected with SARS-CoV-2 continue to have symptoms long past the time that they recovered from the initial phases of COVID-19 disease. Most of the infected patients completely recovered after COVID-19 infection. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |